Yes. As of September 2026, West Pharmaceutical Services, Inc. (WST) is classified as HALAL by Maz Vantage: it passes all 5 published Shariah screening standards it was tested against (AAOIFI, S&P Global, Dow Jones, MSCI and FTSE).
| Standard | Ratios (value / limit) | Result |
|---|---|---|
| AAOIFI | Debt / Mkt Cap (36m) 0.77% / 30% · (Cash+Inv) / Mkt Cap (36m) 2.57% / 30% · Interest income / Revenue 0.06% / 5% | Pass |
| S&P Global | Debt / Mkt Cap (36m) 0.77% / 33% · (Cash+ST Inv) / Mkt Cap (36m) 1.76% / 33% · Receivables / Mkt Cap (36m) 2.83% / 49% · Interest income / Revenue 0.06% / 5% | Pass |
| Dow Jones | Debt / Mkt Cap (24m) 0.77% / 33.33% · (Cash+ST Inv) / Mkt Cap (24m) 1.76% / 33.33% · Receivables / Mkt Cap (24m) 2.83% / 33.33% · Interest income / Revenue 0.06% / 5% | Pass |
| MSCI | Debt / Avg Assets (4Q) 5.57% / 33.33% · (Cash+ST Inv) / Avg Assets (4Q) 13.4% / 33.33% · Receivables / Avg Assets (4Q) 16.5% / 33.33% · Interest income / Revenue 0.06% / 5% | Pass |
| FTSE | Debt / Total Assets 5.00% / 33.33% · (Cash+ST Inv) / Total Assets 11.4% / 33.33% · (Cash+Recv) / Total Assets 29.9% / 33.33% · Interest income / Revenue 0.06% / 5% | Pass |
Yes. As of September 2026, West Pharmaceutical Services, Inc. (WST) is classified as HALAL by Maz Vantage: it passes all 5 published Shariah screening standards it was tested against (AAOIFI, S&P Global, Dow Jones, MSCI and FTSE).
Yes. West Pharmaceutical Services, Inc. is within every AAOIFI limit: debt and interest-bearing cash and investments under 30% of its 36-month average market cap, and interest income under 5% of revenue.
About 0.06% of each dividend: West Pharmaceutical Services, Inc.'s interest income as a share of its revenue. Give that share to charity; the dividend purification calculator works it out per holding.
The screen is rerun on each quarterly report; the figures here are from the balance sheet dated September 30, 2026 (Q3 2026). A status can change from one quarter to the next as debt, cash and market value move.
See also the list of halal stocks, halal healthcare stocks, the halal stock screener, the dividend purification calculator and the zakat calculator.
A mechanical screen of published financial ratios and the company's line of business, not a religious ruling. It does not test every revenue stream; check with a scholar you trust.
West Pharmaceutical Services, Inc. (NYSE: WST) is a Healthcare company (Medical - Instruments & Supplies) with a market capitalization of $29.1B. The Maz Rating grades it against the other companies in its sector.
West Pharmaceutical Services, Inc.'s current Maz Rating and its five factor grades are for members: log in to see them.
At $417.80, West Pharmaceutical Services, Inc. trades at 46.6x trailing earnings, 8.6x sales and 9.9x book value, with an EV/EBITDA of 29.9. Over the last twelve months it generated about $3.4B of revenue and $625M of net income. It runs a gross margin of 37.6%, an operating margin of 23.0% and a net margin of 18.8%. It shows return on equity of 21.1%, return on invested capital of 17.9% and a free cash flow yield of 1.6%. On the balance sheet: a debt-to-equity ratio of 0.10 and a current ratio of 2.82. Over the past 52 weeks the share price ranged from $223.83 to $438.27, with a beta of 1.14.
West Pharmaceutical Services, Inc. pays a dividend yielding 0.22%, with 10% of earnings paid out. Its Maz Dividend Score is 4.70 out of 5, ranked against the other dividend payers in its sector (Safety 4.43, Growth 3.57, Yield 1.03, Consistency 4.90).
17 Wall Street analyst ratings cover the stock: 14 Buy, 2 Hold and 1 Sell, for a Buy consensus. This is the sell side's view, separate from the Maz Rating.
West Pharmaceutical Services, Inc. (WST) specializes in the development, manufacturing, and global distribution of essential containment and delivery solutions for injectable pharmaceuticals and other healthcare products. The company's operations span across the Americas, Europe, the Middle East, Africa, and the Asia Pacific region, structured into two primary business units: Proprietary Products and Contract-Manufactured Products. The Proprietary Products segment offers a comprehensive array of components for injectable packaging, including stoppers and seals, alongside syringe and cartridge parts, which can be customized for specific injectable drug delivery requirements. It also provides advanced drug administration systems designed to enhance safe and effective delivery through sophisticated reconstitution, mixing, and transfer technologies. This segment further supplies ancillary services such as specialized films, protective coatings, cleaning, precision vision inspection, and sterilization processes to elevate the quality of packaging components. Innovative drug containment options, like Crystal Zenith – a cyclic olefin polymer used in vials, syringes, and cartridges – and user-friendly self-injection devices are also key offerings. Additionally, it provides a suite of integrated support services covering analytical laboratory analysis, primary packaging assistance during the pre-approval stage, engineering development, regulatory guidance, and post-purchase technical support. Its clientele primarily includes manufacturers of biologic, generic, and other pharmaceutical products. In contrast, the Contract-Manufactured Products division focuses on the design, production, and automated assembly of various devices for surgical, diagnostic, ophthalmic, and general drug delivery applications, alongside consumer items. This segment caters to pharmaceutical, diagnostic, and medical device manufacturers. The company's offerings reach customers worldwide through a dedicated sales team, an extensive distribution network, and partnerships with contract sales agents and regional distributors. Established in 1923, West Pharmaceutical Services, Inc. is headquartered in Exton, Pennsylvania.
Figures are trailing twelve months unless stated. The Maz Rating and Maz Dividend Score rank a company against its own sector; they are not price targets or recommendations.